Swiss pharma giant Novartis posts better-than-expected fourth-quarter sales

1. Novartis reported Q4 net sales at $13.2 billion, surpassing estimates. 2. 2024 sales guidance raised slightly, driven by Entresto and Cosentyx growth. 3. CEO confident about growth despite Entresto's upcoming patent expiration. 4. Over 30 assets in the pipeline projected to drive long-term growth. 5. Acquisitions of smaller companies are being considered to enhance development.